Who are EZE/simvastatin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ezetimibe + Simvastatin, Ezetimibe and Simvastatin, ezetimibe/simvastatin 10/40, Comparator: ezetimibe and simvastatin, Comparator: Placebo to ezetimibe/simvastatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eze-simvastatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

EZE/simvastatin — Competitive Intelligence Brief

EZE/simvastatin (EZE/simvastatin) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination lipid-lowering agent (ezetimibe + statin). Area: Cardiovascular.

marketed Combination lipid-lowering agent (ezetimibe + statin) NPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

EZE/simvastatin (EZE/simvastatin) — Azienda Ospedaliero Universitaria di Sassari. EZE/simvastatin combines ezetimibe (which blocks cholesterol absorption in the intestine) with simvastatin (which inhibits HMG-CoA reductase to reduce cholesterol synthesis) for dual lipid-lowering action.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
EZE/simvastatin TARGET	EZE/simvastatin	Azienda Ospedaliero Universitaria di Sassari	marketed	Combination lipid-lowering agent (ezetimibe + statin)	NPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin)
Ezetimibe + Simvastatin	Ezetimibe + Simvastatin	Organon and Co	marketed	Combination lipid-lowering agent (ezetimibe + statin)	NPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin)
Ezetimibe and Simvastatin	Ezetimibe and Simvastatin	University of Texas Southwestern Medical Center	marketed	Combination lipid-lowering agent (ezetimibe + statin)	NPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin)
ezetimibe/simvastatin 10/40	ezetimibe/simvastatin 10/40	Organon and Co	phase 3	Combination lipid-lowering agent (ezetimibe + statin)	NPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin)
Comparator: ezetimibe and simvastatin	Comparator: ezetimibe and simvastatin	Organon and Co	phase 3	Combination lipid-lowering agent (ezetimibe + statin)	NPC1L1 transporter (ezetimibe) and HMG-CoA reductase (simvastatin)
Comparator: Placebo to ezetimibe/simvastatin	Comparator: Placebo to ezetimibe/simvastatin	Organon and Co	phase 3	Combination lipid-lowering agent (ezetimibe + statin)	NPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination lipid-lowering agent (ezetimibe + statin) class)

Organon and Co · 4 drugs in this class
Azienda Ospedaliero Universitaria di Sassari · 1 drug in this class
University of Texas Southwestern Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EZE/simvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/eze-simvastatin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab